webinar
Oct. 27-28, 2025, Boston, MA, USA - Booth 114.
Read More

Desmethyl Vc-seco-DUBA

  CAS No.:   Cat No.: BADC-01466 4.5  

Desmethyl Vc-seco-DUBA is an innovative biomedical product used in the treatment of various diseases. It exhibits potent anti-inflammatory properties, making it effective in managing chronic inflammation associated with autoimmune disorders. Its precise mechanism of action involves specifically targeting the overactive immune response and modulating inflammatory pathways. By alleviating inflammation, Desmethyl Vc-seco-DUBA offers promising therapeutic potential in conditions such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Desmethyl Vc-seco-DUBA

Structure of

Quality
Assurance

Worldwide
Delivery

24/7 Customer
Support
Category
ADC Cytotoxin
Molecular Formula
C64H73ClN12O17
Molecular Weight
1317.79

* For research and manufacturing use only. We do not sell to patients.

Size Price Stock Quantity
-- $-- In stock

Looking for different specifications? Click to request a custom quote!

Capabilities & Facilities

Popular Publications Citing BOC Sciences Products
Synonyms
Desmethyl Vc-seco-DUBA
IUPAC Name
[(1S)-1-(chloromethyl)-3-[6-[(4-hydroxybenzoyl)amino]imidazo[1,2-a]pyridine-2-carbonyl]-1,2-dihydrobenzo[e]indol-5-yl] N-[2-[[4-[[(2S)-5-(carbamoylamino)-2-[[(2S)-2-[2-[2-(2,5-dioxopyrrol-1-yl)ethoxy]ethoxycarbonylamino]-3-methylbutanoyl]amino]pentanoyl]amino]phenyl]methoxycarbonyl-methylamino]ethyl]-N-[2-(2-hydroxyethoxy)ethyl]carbamate
Canonical SMILES
CC(C)C(C(=O)NC(CCCNC(=O)N)C(=O)NC1=CC=C(C=C1)COC(=O)N(C)CCN(CCOCCO)C(=O)OC2=CC3=C(C(CN3C(=O)C4=CN5C=C(C=CC5=N4)NC(=O)C6=CC=C(C=C6)O)CCl)C7=CC=CC=C72)NC(=O)OCCOCCN8C(=O)C=CC8=O
InChI
InChI=1S/C64H73ClN12O17/c1-39(2)56(72-62(87)92-32-31-91-29-26-76-53(80)20-21-54(76)81)59(84)71-48(9-6-22-67-61(66)86)58(83)68-43-14-10-40(11-15-43)38-93-63(88)73(3)23-24-74(25-28-90-30-27-78)64(89)94-51-33-50-55(47-8-5-4-7-46(47)51)42(34-65)35-77(50)60(85)49-37-75-36-44(16-19-52(75)70-49)69-57(82)41-12-17-45(79)18-13-41/h4-5,7-8,10-21,33,36-37,39,42,48,56,78-79H,6,9,22-32,34-35,38H2,1-3H3,(H,68,83)(H,69,82)(H,71,84)(H,72,87)(H3,66,67,86)/t42-,48+,56+/m1/s1
InChIKey
KNCLRKFZKRQMMU-NZVNEKQFSA-N

Desmethyl Vc-seco-DUBA, a potent cytotoxic compound widely utilized in cancer research and drug development, boasts a myriad of crucial applications. Here are four key applications:

Antibody-Drug Conjugates (ADCs): The versatile nature of Desmethyl Vc-seco-DUBA allows it to be intricately conjugated to antibodies tailored to specific malignant cell markers, culminating in the creation of ADCs that meticulously target and obliterate cancer cells. This innovative strategy not only mitigates the risk of inadvertent harm to healthy tissues but also amplifies the therapeutic efficacy of cancer treatments. ADCs incorporating this compound represent a nuanced and potentially game-changing departure from conventional chemotherapy, promising heightened effectiveness and improved safety profiles.

Cancer Cell Line Studies: In the realm of preclinical exploration, Desmethyl Vc-seco-DUBA serves as a powerful tool for evaluating its cytotoxic impact on a diverse array of cancer cell lines. Researchers delve into its potency, mode of action, and cellular responses to gauge its therapeutic viability. These investigations are pivotal for unraveling the intricate dance between cancer cells and treatment modalities, paving the way for optimized dosage regimens and a deeper comprehension of treatment outcomes.

Drug Synergy Studies: Embracing a collaborative approach, Desmethyl Vc-seco-DUBA plays a pivotal role in synergy studies, where it is paired with various anticancer agents to appraise potential synergistic effects. The amalgamation of this compound with other drugs unveils synergies that accentuate efficacy while mitigating resistance in cancer cells.

What is Desmethyl Vc-seco-DUBA?

Desmethyl Vc-seco-DUBA is a highly potent cytotoxic agent used as a payload in ADC development. It functions by crosslinking DNA and disrupting replication, leading to cell death, making it suitable for targeting rapidly proliferating cancer cells within antibody-drug conjugate strategies.

7/8/2019

Could you kindly advise how Desmethyl Vc-seco-DUBA contributes to ADC selectivity?

Desmethyl Vc-seco-DUBA is designed to be delivered specifically to antigen-expressing cells through ADC conjugation. Its selective release within the target cell ensures minimal systemic toxicity while maximizing tumor cell apoptosis and overall therapeutic index.

11/5/2021

Could you advise which linker types are compatible with Desmethyl Vc-seco-DUBA?

Desmethyl Vc-seco-DUBA can be conjugated via various cleavable linkers, including peptide or disulfide-based linkers. The linker choice influences drug release kinetics, stability, and ADC efficacy, allowing tailored design for different therapeutic applications.

25/12/2016

Could you kindly advise if Desmethyl Vc-seco-DUBA can be applied in ADC pharmacokinetic studies?

Yes, Desmethyl Vc-seco-DUBA is suitable for ADC pharmacokinetic and pharmacodynamic studies. It allows researchers to assess payload stability, release profiles, and biodistribution, providing essential insights for ADC optimization and preclinical evaluation.

16/8/2016

Good afternoon! What precautions should be taken when working with Desmethyl Vc-seco-DUBA?

Working with Desmethyl Vc-seco-DUBA requires strict laboratory safety, including protective clothing, fume hoods, and proper waste handling. Due to its high cytotoxicity, careful adherence to protocols is essential to prevent accidental exposure or contamination.

18/9/2018

— Dr. David Miller, Senior ADC Researcher (USA)

Desmethyl Vc-seco-DUBA delivered by BOC Sciences had exceptional purity and stability, supporting our ADC studies.

25/12/2016

— Dr. Richard Scott, Bioconjugation Expert (USA)

Desmethyl Vc-seco-DUBA proved reliable for our conjugation trials, maintaining integrity across multiple assays.

18/9/2018

— Ms. Amelie Laurent, Regulatory Manager (France)

The documentation for Desmethyl Vc-seco-DUBA was detailed and compliant, allowing us to use it seamlessly in regulatory submissions.

16/8/2016

— Mr. Peter Novak, Process Development Scientist (Germany)

BOC Sciences delivered Desmethyl Vc-seco-DUBA quickly, and the product met our stringent ADC development requirements.

7/8/2019

— Dr. Helena Costa, ADC Program Lead (Portugal)

The reproducibility of Desmethyl Vc-seco-DUBA enabled our team to generate consistent results across pilot studies.

— Mr. Simon Clark, Senior Chemist (UK)

We received excellent support for Desmethyl Vc-seco-DUBA, including technical guidance on optimal conjugation conditions.

11/5/2021

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Related Products

Contact our experts today for pricing and comprehensive details on our ADC offerings.

You May Also Be Interested In

From cytotoxin synthesis to linker design, discover our specialized services that complement your ADC projects.

ADC Payload Development Biological Payload Chemical Payload Protein Toxin Nanocarrier Microtubule Inhibitors DNA Damaging Agents RNA Polymerase Inhibitors Protein Degraders

Unlock Deeper ADC Insights

Learn more about payload design, linker strategies, and integrated CDMO support through our curated ADC content.

Maytansine and Its Analogues Cytotoxic Agents Used in Antibody–Drug Conjugates Exatecan Mesylate in ADCs: A New Topo I Inhibitor What is Calicheamicin? What is Monomethyl Auristatin E (MMAE)? What is Monomethyl Auristatin F (MMAF)? What is Pyrrolobenzodiazepine (PBD)? Antiviral Potential of Thapsigargin in COVID-19 Research ADC Payloads Explained: Current Types and Cutting-Edge Research Progress Tubulin Inhibitors - Highly Potential ADC Payloads

Explore More ADC Products

Find exactly what your project needs from our expanded range of ADCs, offering flexible options to fit your timelines and goals.

ADC Cytotoxin

Powerful Targeted Cancer Solutions

ADC  Cytotoxin with Linker

Enhanced Stability And Efficacy

ADC Linker

Precise Conjugation For Success

Antibody-Drug  Conjugates (ADCs)

Maximized Therapeutic Performance

Auristatins

Next-Level Tubulin Inhibition

Calicheamicins

High-Impact DNA Targeting

Camptothecins

Advanced Topoisomerase Inhibition

Daunorubicins / Doxorubicins

Trusted Anthracycline Payloads

Duocarmycins

Potent DNA Alkylation Agents

Maytansinoids

Superior Microtubule Disruption

Pyrrolobenzodiazepines

Ultra-Potent DNA Crosslinkers

Traditional Cytotoxic Agents

Proven Chemotherapy Solutions

Cleavable Linker

Precise Intracellular Drug Release

Non-Cleavable Linker

Exceptional Long-Term Stability

Historical Records:
Send Inquiry
Verification code
Inquiry Basket